Compare Inovio Pharmaceuticals Inc (INO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs RLX Technology Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while RLX Technology Inc trades at $2.03 (market cap $2.52B). The key difference: RLX Technology Inc is far larger — about 28.2× Inovio Pharmaceuticals Inc's market cap, and RLX Technology Inc pays a 4.85% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | RLX | |
|---|---|---|
Market Cap | $89.27M | $2.52B |
Sector | Health | Technology |
52-Week High | $2.87 | $2.73 |
52-Week Low | $1.05 | $1.79 |
Enterprise Value | $60.28M | $1.15B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
RLX trades at $2.06, up 0.49% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 revenue of $3.62B and net income of $921.87M. Recent news highlights the vaping industry's projected growth and RLX's cash-rich, debt-free balance sheet.
Outlook is mixed: strong fundamentals and industry tailwinds support growth, but recent EPS misses and a single analyst 'Hold' rating suggest caution. Key risks include regulatory scrutiny and execution challenges in global markets. The stock presents opportunity for long-term investors if expansion succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
